Drug intelligence / Profile preview

CKDB-322

Development stage: Preclinical
Lead developer: CKD Bio
Modality: Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

CKDB-322 is an investigational anti-obesity formulation containing the probiotic *Lactiplantibacillus plantarum* Q180 and the marine microalga *Phaeodactylum tricornutum*. [1, 2, 4] Developed by Chong Kun Dang Bio, it is intended as a functional dietary ingredient for managing adiposity and metabolic health. [1, 7] In preclinical studies, CKDB-322 was shown to suppress fat cell formation (adipogenesis) and fat production (lipogenesis) while increasing fatty acid oxidation and energy metabolism. [1, 4] Its mechanism involves the downregulation of key transcription factors like PPARγ, C/EBPα, and SREBP-1c, and the activation of the AMPK and PPARα pathways. [1, 4] A 12-week clinical trial in overweight adults demonstrated that oral administration of CKDB-322 in a hard capsule form led to significant reductions in body fat mass, body weight, BMI, and serum triglycerides compared to a placebo, with no significant adverse events. [2, 5]

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)SLC7A1 (Cationic amino acid transporter 1)FASN (Fatty acid synthase)SREBP-1 / SREBF1 (SREBP-1)ACC (Acetyl-CoA Carboxylase 1)PPARGC1A (Peroxisome proliferator–activated receptor gamma coactivator 1-alpha)CEBPA (CCAAT enhancer-binding protein alpha)AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on CKDB-322.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKDB-322.

Explore the full profile